Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

@article{Cohen2003PhaseIA,
  title={Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.},
  author={S. Cohen and L. Ho and S. Ranganathan and J. Abbruzzese and R. Alpaugh and M. Beard and N. Lewis and S. Mclaughlin and A. Rogatko and J. P{\'e}rez-Ruixo and Amanda M. Thistle and T. Verhaeghe and Hao Wang and L. Weiner and J. Wright and G. Hudes and N. Meropol},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 7},
  pages={
          1301-6
        }
}
  • S. Cohen, L. Ho, +14 authors N. Meropol
  • Published 2003
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for the function of p21(ras) and other proteins. Given that RAS mutations are nearly universal in pancreatic cancer and R115777 demonstrated preclinical activity against pancreatic cell lines and xenografts, this phase II study was undertaken to determine its clinical activity and effect on target proteins in patients… Expand
148 Citations

Paper Mentions

Interventional Clinical Trial
Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from… Expand
ConditionsPancreatic Cancer
InterventionDrug
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
  • 75
  • Highly Influenced
Phase II study of the farnesyl transferase inhibitor R 115777 in patients with sensitive relapse small-cell lung cancer
  • 6
  • Highly Influenced
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
  • 10
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
  • 123
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
  • L. Gore, S. Holden, +9 authors S. Eckhardt
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
  • 18
Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
  • 24
  • PDF
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
  • 33
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
  • A. Adjei, A. Mauer, +8 authors E. Vokes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
  • 162
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
  • J. Zujewski, I. Horak, +17 authors K. Cowan
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
  • 275
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
  • 126
Drug development in pancreatic cancer
  • 4
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
  • 5,082
  • PDF
...
1
2
...